Data from an interim analysis of the lumateperone large phase III clinical trial for agitation in subjects with dementia is expected by the end of 2018.
Andrew Satlin, MD
Advertisement
Articles by Andrew Satlin, MD
Advertisement
Latest Updated Articles
Andrew Satlin, MD: Lumateperone for Agitation in Patients with Dementia, Alzheimer DiseasePublished: July 23rd 2018 | Updated:
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
NLX-112 Shows Safety and Tolerability in Phase 2a Parkinson Trial, Supporting Further Development
2
Low-Dose Opioids Show Long-Term Dose Stability, Effectiveness in Augmented Restless Legs Syndrome
3
Using Subcutaneous Self-Administered Lecanemab for Alzheimer Disease: Robert Przybelski, MD, MS
4
AskBio’s Late-Onset Pompe Disease Gene Therapy AB-1009 Cleared for Phase 1/2 Trial
5